



PRELIMINARY 2023 CONSOLIDATED REPORT

Board of Administrators of Farmaceutica REMEDIA S.A.

Farmaceutica REMEDIA S.A.

Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197

Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640
remedia@remedia.ro, www.remedia.ro

Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 9.548.082

IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest

IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

PRELIMINARY 2022 CONSOLIDATED REPORT
According to F.S.A. Regulation No. 5/2018

Date of the report: 27.02.2024

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**
Paid-up share capital: **9.548.082 Lei**
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd., pc
330160**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration
with the Trade Register Office: **J20/700/25.07.1991**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(Registration certificate No. AC-1470-7/17.06.2021)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **0,10 Lei**
Position in RNSC Register: **1636**
Total number: **95.480.820**
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010,70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	TOTAL	95.480.820	9.548.082,00 Lei

Organised market on which securities are traded:

Bucharest Stock Exchange – Standard category

The total market value on 27.02.2024 is of 63.972.149 Lei, at a value of a 0,6700 Lei/RMAH share

1. Important events to report

In **February 2023**, Farmaceutica REMEDIA SA sold one pharmaceutical license for the pharmacy Remedia Aviației in Bucharest.

On **02.03.2023**, Farmaceutica REMEDIA SA completed a share buyback transaction carried out with purpose of a Stock Option Plan. Number of shares repurchased on 02.03.2023, according to ASF Decision 122/08.02.2023 is 2.864.425 shares, representing 3% of the share capital. Total number of shares subscribed in operation: 2.864.425 shares, representing 100% of the Offer. Total amount paid by Farmaceutica REMEDIA was 2.148.319 Lei. The price for repurchase was 0,75 Lei per share.

In **July 2023**, Farmaceutica REMEDIA Distribution & Logistics SRL closed the logistics warehouse in Craiova, in order to improve the profitability of the area, by reducing costs.

In **December 2023**, Farmaceutica REMEDIA SA transferred, by sale, to Farmaceutica REMEDIA Distribution & Logistics SRL, one pharmaceutical license regarding the pharmacy Remedia Metalurgiei in Bucharest.

2. The general description of the financial position and of the issuer's performances and of its branches related to 2023

During 01.01.2023 – 31.12.2023, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2023(Lei)	Realisations Jan-Dec 2022 (Lei)	Evolution 2023/2022 (%)
1.	Net sales of goods *	587.774.154	528.160.738	11,29%
2.	Other operating revenues	10.506.076	11.040.025	-4,84%
3.	Total operating income	598.280.230	539.200.763	10,96%
4.	Total operational costs *	590.124.539	532.454.817	10,83%
5.	Operating result	8.155.691	6.745.946	20,90%
6.	Financial result	752.884	311.906	141,38%
7.	Gross result	8.908.575	7.057.852	26,22%

* Including trade discounts granted/received

A breakdown of sales of goods by segments of activity is presented as follows:
Lei

REMEDIA Pharmacies	11.370.803	2%
Distribution	365.349.051	62%
Hospitals & Clinics Distribution	211.054.300	36%
Total	587.774.153	100 %

"Other operating revenues" mainly comprise the following categories of revenues:

- rents
- marketing services
- BD Rowa services
- sale of assets
- other services
- real estate investments

3. The preliminary financial statements as of 31.12.2023 were not audited by the independent financial auditor.

4. Economic-Financial Indicators as of 31.12.2023

LIQUIDITY AND WORKING CAPITAL	FR	FRDL
Current liquidity (Current assets / Current debts)	1,91	1,07
Current assets	15.001.185	258.122.314
Current debts	7.869.129	241.169.185
Degree of indebtedness (Borrowed capital / Equity x 100)	0,00%	0,00%
Borrowed capital	0	0
Equity	52.856.662	18.618.046
Turnover speed for client debit items (Average customer balance /turnover *365)	72 days	103 days
Average customer balance	3.013.747	165.200.056
Net turnover	15.379.933	583.483.500
Turnover speed of stocks (average stock/ net COGS)*365	86 days	28 days
Average stock	2.207.242	41.307.599
COGS net	9.382.832	539.905.120

*including financial leasing

Notes:

¹⁾ **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

²⁾ **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of these companies there is no risk. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

³⁾ **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal, under the circumstances.

⁴⁾ The value of the **No. of storage Days** indicator can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators
 "TARUS" Valentin Norbert TARUS e.U.

by representative
 Valentin-Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - consolidated (Lei)

	31.12.2023	31.12.2022
Net turnover	593.358.927	535.850.640
Income from the sale of goods	589.976.173	530.960.392
Commercial discounts granted	-2.202.020	-2.799.654
Income from services provided and rents	5.584.773	7.689.902
Other operating income	4.921.303	3.350.123
OPERATING INCOME - TOTAL	598.280.230	539.200.763
Expenses with materials	547.527.853	491.419.460
Expenses regarding goods	555.927.973	495.526.556
Commercial discounts received	-11.009.494	-8.770.460
Expenses with raw materials and consumables	1.539.879	3.485.778
Other expenses with materials (inventory objects)	138.925	142.418
Energy and water expenses	930.570	1.035.168
Expenses with personnel	20.619.788	22.132.735
Salaries and allowances	17.707.353	19.309.357
Expenses with insurance and social protection	886.176	903.217
Other personnel expenses	2.026.259	1.920.161
Amortisations and provisions	5.548.329	4.067.397
Amortisations	5.058.187	4.016.528
Net provisions	425.051	-279.307
Losses from receivables	65.092	330.175
Other operating expenses	16.428.569	14.835.225
Expenses on external services	12.592.973	10.711.430
Expenses with other taxes, charges and assimilated payments	2.500.207	1.934.291
Other expenses	1.335.389	2.189.505
OPERATING EXPENSES - TOTAL	590.124.539	532.454.817
OPERATING RESULT	8.155.691	6.745.946
Financial income	1.298.237	844.833
Interest income	869.372	386.605
Income from exchange rate differences	102.132	99.868
Income from dividends	68.305	79.826
Advance payment discounts	258.428	257.985
Other financial income		20.549
Financial expenses	545.353	532.927
Expenses regarding interests	53.571	99.822
Operational leasing interests	67.988	62.476
Expenses due to exchange rate differences	143.570	179.995
Discounts received in advance	0	172.434
Other financial expenses	0	18.200
Other financial expenses - share of the loss from investments accounted for using the equity method	280.224	
FINANCIAL RESULT	752.884	311.906
TOTAL INCOME	599.578.467	540.045.595
TOTAL EXPENSES	590.669.892	532.987.744

GROSS RESULT	8.908.575	7.057.852
Profit tax	1.706.927	1.248.719
TOTAL NET PROFIT of which distributable	7.201.648	5.809.133
Shareholders of the company	7.201.648	5.809.133
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of	7.201.648	5.809.133
Shareholders of the company	7.201.648	5.809.133
Minority interest		
Earnings per share (in Lei)		
- basic	0,0754	0,0608
- diluted	0,0754	0,0608

* retreated according to IFRS 16

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - consolidated (Lei)

	31.12.2023	31.12.2022
ASSETS		
Fixed assets	46.768.058	44.484.546
Tangible assets	27.159.628	24.760.379
Real estate investments	16.364.407	16.545.703
Assets related to the rights of use of leased assets	1.939.283	1.002.094
Software licences	553.105	109.054
Pharmacy licences	628.255	689.200
Participations held in group companies	0	588.620
Participations held in companies outside the group	5.916	5.916
Investments in jointly controlled entities accounted for using the equity method	21.509	
Deposits and guarantees paid	95.955	783.580
Current assets	268.433.018	240.890.648
Stocks	44.334.576	46.262.314
Trade receivables	184.264.742	173.704.309
Other receivables	5.335.665	2.840.680
Cash and cash equivalents	34.498.036	18.083.345
Accrued expenses	560.447	829.696
TOTAL ASSETS	315.761.523	286.204.891
EQUITIES AND DEBTS		
Equities	70.859.551	68.433.434
Share capital	9.860.311	9.860.311
Share premiums	757.485	757.485
Reserves	40.960.056	39.953.756
Current result	7.201.648	5.809.133
Retained earnings	15.231.167	12.477.605
Retained earnings - retreatment	-890.120	-312.229
Profit distribution	0	0
Own shares	-2.260.996	-112.628
Long-term debts	4.248.073	3.175.842
Debts from financial leasing		
Debts from operational leasing		
Provisions		
Debts with deferred income tax	4.248.073	3.175.842
Current debts	240.653.899	214.595.615
Bank loans		
Debts from financial leasing		421.384
Debts from operational leasing	2.132.220	777.861
Suppliers and other similar debts	235.343.070	209.969.435
Provisions	440.784	217.307
Current tax debts	325.137	155.049
Other short-term debts	2.412.688	3.054.580

Total debts	244.901.972	217.771.457
TOTAL EQUITIES AND DEBTS	315.761.523	286.204.891

* retreated according to IFRS 16

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2023

NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25th 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13th 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1st 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1st 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **February 2023**, Farmaceutica REMEDIA SA sold one pharmaceutical license for the pharmacy Remedia Aviației in Bucharest.

On **02.03.2023**, Farmaceutica REMEDIA SA completed a share buyback transaction carried out with purpose of a Stock Option Plan. Number of shares repurchased on 02.03.2023, according to ASF Decision 122/08.02.2023 is 2.864.425 shares, representing 3% of the share capital. Total number of shares subscribed in operation: 2.864.425 shares, representing 100% of the Offer. Total amount paid by Farmaceutica REMEDIA was 2.148.319 Lei. The price for repurchase was 0,75 Lei per share.

In **July 2023**, Farmaceutica REMEDIA Distribution & Logistics SRL closed the logistics warehouse in Craiova, in order to improve the profitability of the area, by reducing costs.

In **December 2023**, Farmaceutica REMEDIA SA transferred, by sale, to Farmaceutica REMEDIA Distribution & Logistics SRL, one pharmaceutical license regarding the pharmacy Remedia Metalurgiei in Bucharest.

In this context, **on 31.12.2023** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

During 2023 Farmaceutica REMEDIA S.A. did not participate in mergers.

During the same period, the company did not alienate assets of significant value (buildings, land, shares, etc.).

Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2023

NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counterperformance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
- Segment reporting
- Retreatment of operational leasing contracts according to IFRS 16

The company holds participations in other companies, in one of them having the control over the financial and operational policies. An entity is consolidated if, based on

Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2023

the assessment of its relations with the Company, it is found that it is controlled by the Company.

The companies whose financial statements are consolidated are:

- Farmaceutica REMEDIA S.A.
- Farmaceutica REMEDIA Distribution & Logistics S.R.L.
- PHARMA EXPERTSPEDITION SRL

Starting with 2012, for the class of tangible assets «Lands and buildings», the Company passed from the cost-based accounting model to the reassessment model.

The financial statements as at 31.12.2023 have been prepared in accordance with International Financial Reporting Standards (IFRS) and their applicability to the financial statements has been audited and reviewed.

The following standards have been revised

IFRS 15 - "Revenue from contracts with customers"

IFRS 16 - " Leases"

IFRS 40 - "Investment property"

IFRS 3 - "Business combinations"

The association with PHARMA EXPERTSPEDITION SRL has been analysed, based on the investment agreement dated 16.12.2021, considering that decisions are taken unanimously by the two partners who each hold 50% of the shares, it is presumed that the entity PHARMA EXPERTSPEDITION SRL is jointly controlled in accordance with the requirements of IFRS 11, it is an entity of the association type with legal personality jointly controlled - IFRS 11.

Therefore the investment in this entity will be accounted for using the "equity method" in accordance with IFRS 11 and IAS 28.

The preliminary consolidated financial statements on 31.12.2023 were not audited by the independent financial auditor.

NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

During the period 01.01.2023 – 31.12.2023, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2023 (Lei)	Realisations Jan-Dec 2022 (Lei)	Evolution 2023/2022 (%)
1.	Net sales of goods *	587.774.154	528.160.738	11,29%
2.	Other operating revenues	10.506.076	11.040.025	-4,84%
3.	Total operating revenues	598.280.230	539.200.763	10,96%

Farmaceutica REMEDIA S.A. – Consolidated financial
statements concluded on 31.12.2023

4.	Total operating costs *	590.124.539	532.454.817	10,83%
5.	Operating result	8.155.691	6.745.946	20,90%
6.	Financial result	752.884	311.906	141,38%
7.	Gross result	8.908.575	7.057.852	26,22%

* Including trade discounts granted/received

“Other operating revenues” mainly comprise the following categories of revenues:

- rents
- marketing services
- BD Rowa services
- sale of assets
- other services
- real estate investments

NOTE 4 ECONOMIC-FINANCIAL INDICATORS

LIQUIDITY AND WORKING CAPITAL	FR	FRDL
Current liquidity (Current assets / Current debts)	1,91	1,07
Current assets	15.001.185	258.122.314
Current debts	7.869.129	241.169.185
Degree of indebtedness (Borrowed capital / Equity x 100)	0,00%	0,00%
Borrowed capital	0	0
Equity	52.856.662	18.618.046
Turnover speed for client debit items (Average customer balance /turnover *365)	72 days	103 days
Average customer balance	3.013.747	165.200.056
Net turnover	15.379.933	583.483.500
Turnover speed of stocks (average stock/ net COGS)*365	86 days	28 days
Average stock	2.207.242	41.307.599
COGS net	9.382.832	539.905.120

* including financial leasing

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the companies are able to cover their short-term debts based on receivables and cash availabilities.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of these companies there is no risk. In the calculation of this indicator, the borrowed capital comprises both bank credits, and

Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2023

financial leasing debts.

³⁾ **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of the indicator is normal, under the circumstances.

⁴⁾ The value of the **No. of storage Days** indicator can be considered as falling within the specifics of the activity.

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2023

NOTE 5 Reporting on activity segments

		Hospitals & Clinics	Distribution	REMEDIA Pharmacies E-commerce	Services Provided and rents	BD ROWA Robots	TOTAL * 2023
Net turnover		211.054.300	365.349.051	11.370.803	4.805.618	779.155	593.358.926
	Income from the sale of goods	211.054.300	367.551.071	11.370.803	0		589.976.173
	Commercial discounts granted	0	-2.202.020	0	0		-2.202.020
	Income from services provided and rents			0	4.805.618	779.155	5.584.773
Other operating income		49.573	81.349	0	4.790.381		4.921.303
OPERATING INCOME - TOTAL		211.103.873	365.430.400	11.370.803	9.595.999	779.155	598.280.230
Expenses with goods		206.129.642	329.406.006	9.382.832	0	0	544.918.479
	Expenses regarding goods	214.874.792	331.650.440	9.402.741		0	555.927.973
	Commercial discounts received	-8.745.150	-2.244.434	-19.909	0		-11.009.494
Gross margin from sales of goods		4.974.231	36.024.394	1.987.972	9.595.999	779.155	53.361.751
							0
Other operating costs		4.051.707	28.787.049	9.280.311	2.257.500	829.493	45.206.060
	Direct costs	2.913.036	19.683.947	2.600.606	99.122	813.910	26.110.621
	Logistics costs	626.759	5.459.549	0			6.086.308
	Indirect costs	511.911	3.643.553	6.679.705	2.158.378	15.583	13.009.130
OPERATING EXPENSES - TOTAL		210.181.348	358.193.055	18.663.143	2.257.500	829.493	590.124.539
							0
Operating result		922.525	7.237.345	-7.292.339	7.338.499	-50.338	8.155.691
Financial result							752.884
Gross result							8.908.575
	Profit tax						-1.706.927
Net profit							7.201.648

Farmaceutica REMEDIA S.A. – Consolidated financial statements concluded on 31.12.2023

NOTE 6 CAPITALS CHANGES

consolidated	Share capital	Legal reserves	Revaluation reserves	Other reserves	Share premiums	Retained earnings	Current result	Own shares	TOTAL
Balance on 01.01.2023	9.860.311	2.122.376	21.435.743	16.395.639	757.485	12.165.375	5.809.133	-112.628	68.433.434
									0
Profit transfer 2022 (PES) to retained earnings		-20				-279.047	279.047		-20
Restoration of profit account retreatments 2022						-4.589.451	4.365.217		-224.234
Profit transfer 2022 (FR) to retained earnings						2.916.025	-2.916.025		0
Profit distribution 2022(FR) to dividends				-1.699.789		-2.916.025			-4.615.814
Profit distribution 2022(FR) to other reserves									0
Account closure 129									0
Profit transfer 2022 (FRDL) to retained earnings						7.537.371	-7.537.371		0
Profit distribution 2022(FRDL) to dividends						-5.000.000			-5.000.000
Profit distribution 2022(FRDL) to other reserves				0		0			0
Accounting result 2023 FR + FRDL							13.000.629		13.000.629
Profit account retreatment						5.798.981	-5.798.981		0
Buildings + lands outputs									0
Revaluation of buildings and lands			2.706.109						2.706.109
Correction of accounting errors						-343.778			-343.778
Reported results - retreating						-913.938			-913.938
Buy own shares								-2.148.368	-2.148.368
Deferred tax									0
Retreatment of operational leasing (IFRS 16)						-34.466			-34.466
Balance on 31.12.2023	9.860.311	2.122.356	24.141.850	14.695.850	757.485	14.341.047	7.201.649	-2.260.996	70.859.551

Farmaceutica REMEDIA S.A. – Consolidated financial statements
concluded on 31.12.2023

NOTE 7 TREASURY FLOWS STATEMENT (RON)

consolidated	12/31/2023	12/31/2022
Cash flows from operating activities		
Collections from the sale of goods and from the provision of services	629.144.905	547.239.304
Other cash inflows	10.715.286	26.234.825
Payments to suppliers of goods and services	577.472.329	520.745.709
Payments to and on behalf of employees (incl. taxes on salaries)	-18.386.001	-20.051.312
Corporate tax payments	-1.605.020	-1.285.506
Payments to other taxes and fees	-18.847.274	-9.078.149
Paid interests	0	-66
Collected interests (current account)	869.372	387
Other cash outflows	-1.196.328	-24.622.509
Total operating cash flow	23.222.610	-1.988.341
Cash flow from investment activities		
Proceeds from the sale of long-term assets and financial investments	345.513	198
Collected interests (from deposits)	0	0
Collected dividends	68.305	80
Payments for the purchase of long-term assets	-1.382.889	-38
Total cash flow from investments	-969.071	240
Cash flow from financing activities		
Short-term loan withdrawals	0	0
Repayment of short-term loans	0	0
Net foreign exchange differences	-4.696	-55
Funding received from shareholders	0	0
Repayments of long-term loans, including interest	0	0
Payments to shareholders (dividends)	-4.189.777	-4.470.000
Payments of own shares	-1.503.869	0
Loans granted between subsidiaries		
Total cash flow from financing	-5.698.341	-4.524.864
Total cash flow	16.555.198	-6.273.695
Cash at the beginning of the period	18.083.345	24.217.749
Cash at the beginning period of the associat	-140.507	139
Cash at the end of the period	34.498.036	18.083.345

Farmaceutica REMEDIA S.A.

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS



PRELIMINARY 2023 UNCONSOLIDATED REPORT

**Board of Administrators of
Farmaceutica REMEDIA S.A.**

Farmaceutica REMEDIA S.A.

Registered office: Deva 330040, Nicolae Balcescu Bld. no 2 (former No. 43 Dorobantilor Street), Hunedoara County, Telephone: + 40 254 223 260, Fax: +40 254 226 197

Branch office: Bucharest, 041836, sector 4, Bld. Metalurgiei 78, Telephone/fax: + 40 213 211 640
remedia@remedia.ro, www.remedia.ro

Trade Register J20/700/1991, TIN: RO2115198; Share capital: RON 9.548.082

IBAN: RO61 BTRL RONC RT00 G713 3302, Transilvania Bank, Bucharest

IBAN: RO33 RZBR 0000 0600 0266 5747, Raiffeisen Unirii, Bucharest

PRELIMINARY 2023 REPORT - unconsolidated
According to F.S.A. Regulation No. 5/2018
Date of the report: 27.02.2024

Name of the commercial company: **Farmaceutica REMEDIA S.A.**

Subscribed share capital: **9.548.082 Lei**
Paid-up share capital: **9.548.082 Lei**
Registered office: **DEVA, No. 2 Nicolae Bălcescu Bd., pc
330160**
Tel./fax.: **+40 254 223 260, +40 254 226 197**
No. and date of registration
with the Trade Register Office: **J20/700/25.07.1991**
Tax registration number: **RO2115198**

Securities: **RMAH shares**
(Registration certificate No. AC-1470-7/17.06.2021)
Type: **Common Nominative**
Date of registration: **17.03.1997**
Nominal value: **0,10 Lei**
Position in RNSC Register: **1636**
Total number: **95.480.820**
R.N.S.C. code of shares: **16368**

Registration	Date	Number of shares	Issue value
1	10.11.1999	3.370.107	337.010.70 Lei
2	06.09.2001	1.500.000	150.000,00 Lei
3	23.07.2003	42.402	4.240,20 Lei
4	05.01.2006	5.696.471	569.647,10 Lei
5	21.12.2007	87.905.969	8.790.596,90 Lei
6	08.04.2009	7.574.851	757.485,10Lei
7	09.06.2021	- 10.608.980	- 1.060.898,00 Lei
	TOTAL	95.480.820	9.548.082,00 Lei

Organised market on which securities are traded:

Bucharest Stock Exchange – Standard category

The total market value on 27.02.2024 is of 63.972.149 Lei, at a value of a 0,6700 Lei/RMAH share

1. Important events to report

In **February 2023**, Farmaceutica REMEDIA SA sold one pharmaceutical license for the pharmacy Remedia Aviației in Bucharest.

On **02.03.2023**, Farmaceutica REMEDIA SA completed a share buyback transaction carried out with purpose of a Stock Option Plan. Number of shares repurchased on 02.03.2023, according to ASF Decision 122/08.02.2023 is 2.864.425 shares, representing 3% of the share capital. Total number of shares subscribed in operation: 2.864.425 shares, representing 100% of the Offer. Total amount paid by Farmaceutica REMEDIA was 2.148.319 Lei. The price for repurchase was 0,75 Lei per share.

In **December 2023**, Farmaceutica REMEDIA SA transferred, by sale, to Farmaceutica REMEDIA Distribution & Logistics SRL, one pharmaceutical license regarding the pharmacy Remedia Metalurgiei in Bucharest.

2. The general description of the financial position and of the issuer's performances and of its branches related to 2023

During the period 01.01.2023 – 31.12.2023 the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2023 (Lei)	Realisations Jan-Dec 2022 (Lei)	Evolution 2023/2022 (%)
1.	Net sales of goods *	11.370.803	15.084.967	-24,62%
2.	Other operating revenues	9.582.946	6.096.588	57,19%
3.	Total operating revenues	20.953.750	21.181.555	-1,08%
4.	Total operating costs *	21.936.274	23.565.548	-6,91%
5.	Operating result	-982.525	-2.383.993	58,79%
6.	Financial result	5.357.387	5.300.018	1,08%
7.	Gross result (profit)	4.374.862	2.916.026	50,03%

* Including commercial discounts granted/received

"Other operating revenues" mainly comprise the following categories of revenues:

- rents – 33% out of "Other operating revenues"
- BD Rowa services – 8% out of "Other operating revenues"
- sales of assets – 18% out of "Other operating revenues"
- real estate investments - 40% out of "Other operating revenues"
- other services – 1% out of "Other operating revenues"

3. The financial statements as at 31.12.2023 were not audited by the independent financial auditor.

4. Economic-Financial Indicators

LIQUIDITY AND WORKING CAPITAL	31.12.2023
Current liquidity (Current assets / Current debts)	1,91
Current assets	15.001.185
Current debts	7.869.129
Degree of indebtedness (Borrowed capital / Equity x 100)	0,00%
Borrowed capital	0
Equity	52.856.662
Turnover speed for client debit items (Average customer balance /turnover *365)	72 days
Average customer balance	3.013.747
Net turnover	15.379.933
Turnover speed of stocks (average stock balance/cogs)*365	86 days
Average stock balance	2.207.242
Net COGS	9.382.832

Notes:

¹⁾ **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

²⁾ **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

³⁾ **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 72 days is a normal one under the circumstances.

⁴⁾ The value of the **No. of Storage Days** indicator, can be considered as falling within the specifics of the activity, increase in the indicator being caused by the decrease in the number of pharmaceutical units.

Chairman of the Board of Administrators
"TARUS" Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF COMPREHENSIVE INCOME - unconsolidated (Lei)

	31.12.2023	31.12.2022
Net turnover	15.379.933	18.307.055
Income from the sale of goods	11.370.803	15.084.967
Commercial discounts granted	0	0
Income from services provided and rents	4.009.129	3.222.088
Other operating income	5.573.817	2.874.500
OPERATING INCOME - TOTAL	20.953.750	21.181.555
Expenses with materials	9.998.633	13.608.407
Expenses regarding goods	9.402.741	13.058.243
Commercial discounts received	-19.909	-76.566
Expenses with raw materials and consumables	385.524	375.199
Other expenses with materials (inventory objects)	32.451	47.316
Energy and water expenses	197.826	204.215
Expenses with personnel	4.392.156	4.417.169
Salaries and allowances	3.538.249	3.502.561
Expenses with insurance and social protection	94.608	165.582
Other personnel expenses	759.299	749.026
Amortisations and provisions	4.073.840	2.716.674
Amortisations	4.073.390	2.717.999
Net provisions	0	-9.191
Losses from receivables	450	7.865
Other operating expenses	3.471.646	2.823.298
Expenses on external services	1.393.114	1.334.698
Expenses with other taxes, charges and assimilated payments	1.197.106	802.627
Other expenses	881.426	685.973
OPERATING EXPENSES - TOTAL	21.936.274	23.565.548
OPERATING RESULT	-982.525	-2.383.993
Financial income	5.413.254	5.321.320
Interest income	343.634	237.069
Income from exchange rate differences	1.314	4.424
Income from dividends	5.068.305	5.079.826
Advance payment discounts	0	0
Other financial income	0	0
Financial expenses	55.867	21.301
Expenses with interests	53.571	0
Expenses due to exchange rate differences	2.296	21.301
Discounts received in advance	0	0
Other financial expenses		
FINANCIAL RESULT	5.357.387	5.300.018
TOTAL INCOME	26.367.003	26.502.875
TOTAL EXPENSES	21.992.142	23.586.849
GROSS RESULT	4.374.862	2.916.026

Profit tax	0	0
TOTAL NET PROFIT of which distributable	4.374.862	2.916.026
Shareholders of the company	4.374.862	2.916.026
Minority interest		
Other elements of comprehensive income		
Revaluation of tangible assets		
Tax related to other elements of comprehensive income		
Minority interest		
COMPREHENSIVE INCOME AFFERENT TO THE PERIOD - TOTAL of	4.374.862	2.916.026
Shareholders of the company	4.374.862	2.916.026
Minority interest		
Earnings per share (in Lei)		
- basic	0,0458	0,0305
- diluted	0,0458	0,0305

Chairman of the Board of Administrators
 "TARUS" - Valentin Norbert TARUS e.U.

by representative
 Valentin – Norbert TARUS

Farmaceutica REMEDIA SA

STATEMENT OF FINANCIAL POSITION - unconsolidated (Lei)

	31.12.2023	31.12.2022
ASSETS		
Fixed assets	49.600.603	47.370.124
Tangible assets	26.658.751	23.487.049
Real estate investments	16.364.407	16.545.703
Operational leasing assets	667.684	
Software licences	76.006	63.649
Pharmacy licences	178.255	689.200
Participations held in group companies	602.200	891.720
Participations held in companies outside the group	5.916	5.916
Deposits and guarantees paid	5.047.385	5.686.888
Current assets	15.001.185	14.704.786
Stocks	2.298.411	2.179.248
Trade receivables	4.260.102	3.085.858
Other receivables	459.956	542.286
Cash and cash equivalents	7.982.716	8.897.395
Accrued expenses	372.077	439.812
TOTAL ASSETS	64.973.864	62.514.723
EQUITIES AND DEBTS		
Equities	52.856.662	52.977.439
Share capital	9.860.311	9.860.311
Share premiums	757.485	757.485
Reserves	40.426.106	39.419.786
Current result	4.374.862	2.916.026
Retained earnings	11.123	448.688
Retained earnings - retreatment	-312.229	-312.229
Profit distribution	0	0
Own shares	-2.260.996	-112.628
Long-term debts	4.248.073	3.175.842
Debts from financial leasing		
Debts from operational leasing		
Provisions	4.248.073	3.175.842
Debts with deferred income tax		
	7.869.129	6.361.443
Current debts		
Bank loans		
Debts from financial leasing	826.155	
Suppliers and other similar debts	5.908.015	5.531.838
Provisions		
Current tax debts		
Other short-term debts	1.134.959	829.605

Total debts	12.117.202	9.537.284
TOTAL EQUITIES AND DEBTS	64.973.864	62.514.723

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin – Norbert TARUS

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

NOTE 1 INFORMATION ABOUT THE COMPANY

Farmaceutica REMEDIA S.A. (« the Company ») is a commercial company with registered office in Deva, No. 2 Nicolae Balcescu Bld. (former Str. Dorobantilor 43), Hunedoara County, Romania.

On **July 25th 1991**, it was established as a commercial company with fully state-owned capital by reorganisation of Oficiul Farmaceutic Deva.

On **October 13th 2000**, V. TARUS RoAgencies S.R.L. purchased from FPS the majority shares package (55,802%).

On **January 1st 2006**, Farmaceutica REMEDIA S.A. merged by absorption with V. TARUS RoAgencies S.R.L.

According to Law 95/2006, republished in August 2015, companies were prohibited from carrying out, at the same time, wholesale and retail distribution of medicines. (Art. 800 paragraph 2). Therefore,

On **January 1st 2016** Farmaceutica REMEDIA S.A. completed the transfer to Farmaceutica REMEDIA Distribution & Logistics S.R.L., a new company, 100% owned, of the wholesale distribution activities of medicines together with related activities (logistic services, registration of pharmaceutical products, promotion and marketing of medicines, etc.), Farmaceutica REMEDIA S.A. kept the operation of the chain of pharmacies and local offices.

In **February 2023**, Farmaceutica REMEDIA SA sold one pharmaceutical license for the pharmacy Remedia Aviației in Bucharest.

On **02.03.2023**, Farmaceutica REMEDIA SA completed a share buyback transaction carried out with purpose of a Stock Option Plan. Number of shares repurchased on 02.03.2023, according to ASF Decision 122/08.02.2023 is 2.864.425 shares, representing 3% of the share capital. Total number of shares subscribed in operation: 2.864.425 shares, representing 100% of the Offer. Total amount paid by Farmaceutica REMEDIA was 2.148.319 Lei. The price for repurchase was 0,75 Lei per share.

In **December 2023**, Farmaceutica REMEDIA SA transferred, by sale, to Farmaceutica REMEDIA Distribution & Logistics SRL, one pharmaceutical license regarding the pharmacy Remedia Metalurgiei in Bucharest.

In this context, **on 31.12.2023** Farmaceutica REMEDIA S.A. held a majority participation (100%) in the company Farmaceutica REMEDIA Distribution & Logistics S.R.L. and a 50% participation in the company PHARMA EXPERTSPEDITION S.R.L.

During 2023 Farmaceutica REMEDIA S.A. did not participate in mergers.

During the same period, the company did not alienate assets of significant value (buildings, land, shares, etc.).

NOTE 2 BASES FOR DRAFTING THE FINANCIAL STATEMENTS

The financial statements of the company were drafted in compliance with the provisions of Order No. 2844/2016 for the approval of the Accounting regulations in compliance with the International Financial Reporting Standards (IFRS), adopted by the

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

European Union, applicable to commercial companies whose securities are admitted to trading on a regulated market, with all subsequent modifications and clarifications.

For the purpose of drafting these financial statements, in compliance with the legislative provisions in Romania, the functional currency of the company is considered to be the Romanian Leu (RON).

For all the periods until the year concluded on 31 December 2011, inclusive, the company prepared the financial statements in compliance with the Romanian Accounting Standards (RAS). The financial statements for the year concluded on 31 December 2012, are the first financial statements drafted in compliance with the International Financial Reporting Standards (IFRS), as adopted by the European Union.

The financial statements were drafted based on the historic cost, except for the buildings and lands which are assessed at their fair value (the market value determined by assessment by an expert evaluator). The historic cost is generally based on the fair value of the counterperformance carried out in exchange for the assets.

The company presents in the financial statements at the fair value all the asset and passive elements for which the assessment at the fair value is imposed, the methods used for its establishment being inventory and revaluation (IFRS 13).

The company does not have financial statements which would involve the use of other fair value estimation methods.

Certain amounts from the financial position statement, the global result statement, as well as from the explanatory notes were reclassified to ensure comparability between previous years and the current year.

Preparation of the IFRS financial statements involves the use by the management of professional judgments, estimations and hypotheses that may affect the application of the accounting policies and the reported value of assets, debts, incomes and expenses. Under these conditions, the actual results may differ from the estimated values. Estimates and hypotheses that are based on them are periodically reviewed. The review of accounting estimates is recognised during the period in which the estimate was reviewed and in the future periods affected. The following are critical professional judgments / reasoning which the Company management made with a significant impact on the values recognized in the financial statements:

- Lifespan of fixed assets
- Deferred taxes
- Provisions
- Segment reporting
- Retreatment of operational leasing contracts according to IFRS 16

The company holds participations in other companies, in one of them having the control over the financial and operational policies. An entity is consolidated if, based on the assessment of its relations with the Company, it is found that it is controlled by the Company.

The companies whose financial statements are consolidated are:

- Farmaceutica REMEDIA S.A.
- Farmaceutica REMEDIA Distribution & Logistics S.R.L.
- PHARMA EXPERTSPEDITION SRL

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

Starting with 2012, for the class of tangible assets «Lands and buildings», the Company passed from the cost-based accounting model to the reassessment model.

The financial statements as at 31.12.2023 have been prepared in accordance with International Financial Reporting Standards (IFRS) and their applicability to the financial statements has been audited and reviewed.

The following standards have been revised

IFRS 15 - "Revenue from contracts with customers"

IFRS 16 - " Leases"

IFRS 40 - "Investment property"

IFRS 3 - "Business combinations"

The association with PHARMA EXPERTSPEDITION SRL has been analysed, based on the investment agreement dated 16.12.2021, considering that decisions are taken unanimously by the two partners who each hold 50% of the shares, it is presumed that the entity PHARMA EXPERTSPEDITION SRL is jointly controlled in accordance with the requirements of IFRS 11, it is an entity of the association type with legal personality jointly controlled - IFRS 11.

Therefore the investment in this entity will be accounted for using the "equity method" in accordance with IFRS 11 and IAS 28.

The preliminary unconsolidated financial statements on 31.12.2023 were not audited by the independent financial auditor.

NOTE 3 SALES REVENUES AND OTHER OPERATING REVENUES

During the period 01.01.2023 – 31.12.2023, the commercial company Farmaceutica REMEDIA S.A. recorded the following financial results:

Crt. No.	Indicator	Realisations Jan-Dec 2023 (Lei)	Realisations Jan-Dec 2022 (Lei)	Evolution 2023/2022 (%)
1.	Net sales of goods *	11.370.803	15.084.967	-24,62%
2.	Other operating revenues	9.582.946	6.096.588	57,19%
3.	Total operating revenues	20.953.750	21.181.555	-1,08%
4.	Total operating costs *	21.936.274	23.565.548	-6,91%
5.	Operating result	-982.525	-2.383.993	58,79%
6.	Financial result	5.357.387	5.300.018	1,08%
7.	Gross result	4.374.862	2.916.026	50,03%

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

* Including trade discounts granted/received

“Other operating revenues” mainly comprise the following categories of revenues:

- rents – 33% out of “Other operating revenues”
- BD Rowa services – 8% out of “Other operating revenues”
- sales of assets – 18% out of “Other operating revenues”
- real estate investments - 40% out of “Other operating revenues”
- other services – 1% out of “Other operating revenues”

NOTE 4 ECONOMIC-FINANCIAL INDICATORS

LIQUIDITY AND WORKING CAPITAL	31.12.2023
Current liquidity (Current assets / Current debts)	1,91
Current assets	15.001.185
Current debts	7.869.129
Degree of indebtedness (Borrowed capital / Equity x 100)	0,00%
Borrowed capital	0
Equity	52.856.662
Turnover speed for client debit items (Average customer balance / turnover *365)	72 days
Average customer balance	3.013.747
Net turnover	15.379.933
Turnover speed of stocks (average stock/ net COGS)*365)	86 days
Average stock	2.207.242
COGS net	9.382.832

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors, certifying that the company is capable of covering its short-term debts based on the receivables and cash availability.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. The 0% value indicates that the company has no financing or liquidity problem. In the calculation of this indicator, the borrowed capital comprises both bank credits, and financial leasing debts.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

which debtors pay their debts to the company. Considering the dynamics of sales and the specific of collecting receivables in the distribution of drugs, we believe that the value of 72 days is a normal one under the circumstances.

⁴⁾ The value of the **No. of Storage Days** indicator, can be considered as falling within the specifics of the activity, increase in the indicator being caused by the decrease in the number of pharmaceutical units.

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

NOTE 5 Reporting on activity segments

		Remedia farmacies	BD ROWA/Robots	Rents for spaces/auto	Provided services	TOTAL * 2023
Net turnover		11.370.803	779.155	3.159.728	70.246	15.379.932
	Income from the sale of goods	11.370.803				11.370.803
	Commercial discounts granted	0		0	0	0
	Income from services provided and rents	0	779.155	3.159.728	70.246	4.009.129
Other operating revenues		0			5.573.817	5.573.817
OPERATING REVENUES - TOTAL		11.370.803	779.155	3.159.728	5.644.063	20.953.749
						0
Expenses with goods		9.382.832	0	0	0	9.382.832
	Expenses regarding goods	9.402.741	0	0	0	9.402.741
	Commercial discounts received	-19.909		0	0	-19.909
Gross margin from sales of goods		1.987.972	0	0	0	1.987.972
						0
Other operating costs		9.280.311	829.493	2.353.081	90.558	12.553.443
	Direct costs	2.600.606	813.910	496.919	49.292	3.960.727
	Logistics costs	0		0	0	0
	Promotion costs	0		0	0	0
	Indirect costs	6.679.705	15.583	1.856.162	41.266	8.592.716
OPERATING EXPENSES - TOTAL		18.663.143	829.493	2.353.081	90.558	21.936.274
						0
Operating result		-7.292.339	-50.338	806.647	5.553.505	-982.525
Financial result						5.357.387
Gross result						4.374.862
	Profit tax					0
Net profit						4.374.862

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

NOTE 6 CAPITALS CHANGE

Sold on 01.01.2023	Share capital	Legal reserves	Revaluation reserves	Other reserves	Share premiums	Retained earnings	Current result	Own shares	TOTAL
	9.860.311	2.121.796	21.435.741	15.862.249	757.485	136.459	2.916.025	-112.628	52.977.438
									0
Profit transfer 2022 to retained earnings						2.916.025	-2.916.025		0
Profit distribution 2022 to dividends				-1.699.789		-2.916.025			-4.615.814
Profit distribution 2022 to other reserves									0
Profit distribution 2022 to other reserves									0
Result 2023							4.374.862		4.374.862
Legal reserve 2022									0
Account closure 129									0
Buildings + lands outputs									0
Revaluation of buildings and lands			2.706.109						2.706.109
Deferred tax									0
Correction of accounting errors 2022						-437.565			-437.565
Buy own shares								-2.148.368	-2.148.368
Balance on 31.12.2023	9.860.311	2.121.796	24.141.850	14.162.460	757.485	-301.106	4.374.862	-2.260.996	52.856.662

Farmaceutica REMEDIA S.A. – Unconsolidated financial statements concluded on 31.12.2023

NOTE 7 TREASURY FLOWS STATEMENT (RON)

unconsolidated	12/31/2023	12/31/2022
Cash flows from operating activities		
Collections from the sale of goods and from the provision of services	18.928.342	20.679.779
Other cash inflows	517.672	1.248.092
Payments to suppliers of goods and services	-14.532.382	-19.895.308
Payments to and on behalf of employees (incl. taxes on salaries)	-3.540.629	-3.627.936
Corporate tax payments	0	0
Payments to other taxes and fees	-1.703.271	-2.133.197
Paid interests		
Collected interests (current account)	343.634	237
Other cash outflows	-647.359	-1.340.013
Total operating cash flow	-633.993	-4.831.513
Cash flow from investment activities		
Proceeds from the sale of long-term assets and financial investments	345.513	198
Collected interests (from deposits)	0	
Collected dividends	5.068.305	5.079.826
Payments for the purchase of long-term assets		
Total cash flow from investments	5.413.818	5.277.526
Cash flow from financing activities		
Short-term loan withdrawals	0	
Repayment of short-term loans	0	
Net foreign exchange differences	-858	-9
Funding received from shareholders		
Repayments of long-term loans, including interest		
Payments to shareholders (dividends)	-4.189.777	-4.470.000
Payments of own shares	-1.503.869	
Loans granted between subsidiaries		
Total cash flow from financing	-5.694.504	-4.478.950
Total cash flow	-914.679	-4.032.938
Cash at the beginning of the period	8.897.395	12.930.332
Cash at the end of the period	7.982.716	8.897.395

Farmaceutica REMEDIA S.A.

Chairman of the Board of Administrators
"TARUS" - Valentin Norbert TARUS e.U.

by representative
Valentin-Norbert TARUS